Cell Therapy News Volume 21.25 | Jul 13 2020

    By
    Justin.choi
    -
    0
    28







    2020-07-13 | CTN 21.25


    Cell Therapy News by STEMCELL Technologies
    Vol. 21.25 – 13 July, 2020
    TOP STORY

    Metabolic Engineering Generates a Transgene-Free Safety Switch for Cell Therapy

    Using genome editing methods, scientists disrupted uridine monophosphate synthetase (UMPS) in the pyrimidine de novo synthesis pathway in cell lines, pluripotent cells and primary human T cells.
    [Nature Biotechnology]

    AbstractPress Release


    Dr. Daniel Dever, describes a CRISPR-Cas9-based protocol for gene editing hematopoietic stem cells in this on-demand webinar.
    PUBLICATIONSRanked by the impact factor of the journal

    Engineered Off-The-Shelf Therapeutic T Cells Resist Host Immune Rejection

    Cells co-expressing chimeric antigen receptors and alloimmune defense receptor persisted in mice and produced sustained tumor eradication in two mouse models of allogeneic T-cell therapy of hematopoietic and solid cancers.
    [Nature Biotechnology]

    Abstract

    IgG-Cleaving Endopeptidase Enables In Vivo Gene Therapy in the Presence of Anti-AAV Neutralizing Antibodies

    Investigators studied if imlifidase could eliminate anti-adeno-associated virus antibodies in the context of gene therapy.
    [Nature Medicine]

    Abstract

    Suprachoroidal Gene Transfer with Nonviral Nanoparticles

    Suprachoroidal injection of nanoparticles containing a VEGF-binding protein expression plasmid significantly suppressed VEGF-induced vascular leakage and neovascularization demonstrating therapeutic potential.
    [Science Advances]

    AbstractPress Release

    Self-Assembled Cell Sheets Composed of Mesenchymal Stem Cells and Gelatin Nanofibers for the Treatment of Full-Thickness Wounds

    Dorsal wounds transplanted with the cell sheets exhibited higher wound-healing rates when a high concentration of gelatin was immobilized on the surfaces of the nanofibrils.
    [Biomaterials Science]

    Abstract

    Transamniotic Mesenchymal Stem Cell Therapy for Neural Tube Defects Preserves Neural Function through Lesion-Specific Engraftment and Regeneration

    Researchers report that transamniotic bone marrow-derived mesenchymal stem cell therapy for neural tube defects during early development may achieve beneficial functional recovery.
    [Cell Death & Disease]

    Full Article

    Development of a Clinical Candidate AAV3 Vector for Gene Therapy of Hemophilia B

    The authors developed an adeno-associated virus 3 (AAV3) vector incorporating a compact yet powerful liver-directed promoter as well as optimized human coagulation factor IX cDNA sequence inserted between two AAV3 inverted terminal repeats.
    [Human Gene Therapy]

    Abstract

    Regenerative Effects of Human Chondrocyte Sheets in a Xenogeneic Transplantation Model Using Immune‐Deficient Rats

    Researchers investigated the regenerative effects of human chondrocyte sheets on articular cartilage in a xenogeneic transplantation model using immune‐deficient rats.
    [Journal of Tissue Engineering and Regenerative Medicine]

    Abstract

    Defining an Optimal Dual-Targeted CAR T-Cell Therapy Approach Simultaneously Targeting BCMA and GPRC5D to Prevent BCMA Escape-Driven Relapse in Multiple Myeloma

    Scientists demonstrated that simultaneous targeting of an additional antigen—here, G protein-coupled receptor class-C group-5 member-D (GPRC5D)—could prevent B-cell maturation antigen escape–mediated relapse in a model of multiple myeloma. To identify an optimal approach, they compared subtherapeutic doses of different forms of dual-targeted cellular therapy.
    [Blood Cancer Discovery]

    Abstract

    Subscribe to Science News for free weekly science newsletters.
    REVIEWS

    Current Progress in Stem Cell Therapy for Type 1 Diabetes Mellitus

    Researchers discuss the current research advances in strategies to obtain insulin-producing cells from different precursor cells and in stem cell-based therapies for diabetes.
    [Stem Cell Research & Therapy]

    Full Article

    INDUSTRY AND POLICY NEWS

    Fate Therapeutics Announces FDA Clearance of IND Application for First-Ever iPSC-derived CAR T-Cell Therapy

    Fate Therapeutics, Inc. announced that the FDA has cleared the company’s Investigational New Drug application for FT819, an off-the-shelf allogeneic chimeric antigen receptor T-cell therapy targeting CD19+ malignancies.
    [Fate Therapeutics, Inc.]

    Press Release

    ‘I Feel Like I Am Not Welcome’: Medical, Doctoral Students from Abroad Grapple with Uncertainty from New ICE Rules

    International students completing their medical and doctoral degrees in the US are wrestling with frustration and uncertainty following the release of federal rules this week that could bar them from staying in the country.
    [STAT]

    Editorial

    FEATURED EVENT

    From Stem Cells to Human Development

    September 8 – September 11
    Virtual

    > See All Events

    JOB OPPORTUNITIES

    Engineer – Cell Therapy

    Oslo University Hospital – Oslo, Norway

    Senior Scientist – Process Development Lab, Gene and Cell Therapy

    Genezen Laboratories – Indianapolis, Indiana, United States

    Quality Control Manager – Gene and Cell Therapy

    Genezen Laboratories – Indianapolis, Indiana, United States

    Scientific Project Manager – Neurofibromatosis Type 1 Gene Therapy

    Gilbert Family Foundation – Detroit, Michigan, United States

    Postdoctoral Fellow – Immune and Stem Cell Engineering

    Terasaki Institute for Biomedical Innovation – Los Angeles, California, United States

    Faculty Positions – Regenerative Medicine

    Guangzhou Regenerative Medicine and Health Guangdong Laboratory – Guangzhou, China

    > See All Jobs

    Submit an article, publication, job or event
    Brought to you by
    stemcell-logo-for newsletter-2
    Cell Therapy News Twitter